No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Silajdžić, Edina ^a   Minthon, Lennart ^b,c   Björkqvist, Maria ^a   Hansson, Oskar ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CLUSTERIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RISK FACTOR;

ADULT; AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLUSTERIN; DEMENTIA; DEPRESSION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK; SWEDEN;

EID: 84870359901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050237     Document Type: Article

References (34)

1. Blennow K, de Leon MJ, Zetterberg H, (2006) Alzheimer's disease. The Lancet 368: 387-403.
2. Perrin RJ, Fagan AM, Holtzman DM, (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
3. Blennow K, Hampel H, Weiner M, Zetterberg H, (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-144.
4. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, et al. (2012) Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95: 579-593.
5. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
6. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
7. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303: 1832-1840.
8. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, et al. (1994) Purification and characterization of brain clusterin. Biochem Biophys Res Commun 204: 1131-1136.
9. Nuutinen T, Suuronen T, Kauppinen A, Salminen A, (2009) Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 61: 89-104.
10. Murphy BF, Saunders JR, O'Bryan MK, Kirszbaum L, Walker ID, et al. (1989) SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol 1989:1: 551-554.
11. McDonald JF, Nelsestuen GL, (1997) Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry 36: 7464-7473.
12. Michel D, Moyse E, Trembleau A, Jourdan F, Brun G, (1997) Clusterin/ApoJ expression is associated with neuronal apoptosis in the olfactory mucosa of the adult mouse. J Cell Sci 110: 1635-1645.
13. Kim N, Han JY, Roh GS, Kim HJ, Kang SS, et al. (2012) Nuclear clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. Alcohol Clin Exp Res 36: 72-82.
14. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J, (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29: 5380-5389.
15. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM, (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA 305: 1322-1326.
16. Xing YY, Yu JT, Cui WZ, Zhong XL, Wu ZC, et al. (2012) Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J Alzheimers Dis 29: 515-519.
17. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, et al. (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67: 739-748.
18. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, et al. (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59: 212-217.
19. Ioannidis JP, Panagiotou OA, (2011) Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305: 2200-2210.
20. Association AP (1987) Diagnostic and Statistical Manual of Mental Disorders. 3rd, revised ed. Washington DC: American Psychiatric Association.
21. McKhann G, Drachman D, Folstein M, Folstein M, Katzman R, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
22. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, et al. (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-260.
23. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, et al. (2000) Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59: 23-30.
24. McKeith IG, Perry EK, Perry RH, (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53: 902-905.
25. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, et al. (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58: 1803-1809.
26. Cubedo J, Padró T, García-Moll X, Pintó X, Cinca J, et al. (2011) Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction. J Proteome Res 10: 211-20.
27. Schürmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, et al. (2011) Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 25: 421-424.
28. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, et al. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-234.
29. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413.
30. IJsselstijn L, Dekker LJ, Koudstaal PJ, Hofman A, Sillevis Smitt PA, et al. (2011) Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 10: 2006-2010.
31. Raison CL, Capuron L, Miller AH, (2006) Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31.
32. Maes M, (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 664-675.
33. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, et al. (1997) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66: 1-11.
34. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A, (1997) Acute phase proteins in major depression. J Psychosom Res 43: 529-534.